| INTRODUC TI ON
Haemophilia A, an X-linked bleeding disorder is characterized by reduced levels of coagulation factor VIII. 1 The treatment of haemophilia A involves replacement of FVIII with factor concentrates. The replacement therapy is hindered by the development of neutralising antibodies against the infused FVIII. Antibodies which neutralize the replaced factors are called as inhibitors. These inhibitors have been identified to be predominantly immunoglobulin IgG1 and IgG4
subtype. 2 The prevalence of inhibitors in patients with severe haemophilia vary from 25%-30% 3 and has been identified as the major complication in the treatment of haemophilia. The reason why inhibitors develop only in a subset of patients remains a pertinent question. Biological components like F8 gene mutation and haplotypes, 4 immunophenotype of Treg population, 5, 6 ethnicity, 7 positive family history 8 and patient-related modifiers like age of the first exposure to FVIII products, intensity of treatment or type of clotting factor used have been implicated to the development of inhibitors. 9, 10 These causative factors have been studied in different populations with varying conclusions. Mutations in the F8 gene have been identified to be closely associated with the development of inhibitors in haemophilia A. 10, 11 HLA polymorphisms have also been identified to be involved in the formation of inhibitors. 12 Polymorphisms in immune-regulatory genes (CTLA-4, IL-10, TNF-α) have been studied in different populations, and their associations with inhibitor formation have been identified. [13] [14] [15] Exposures to different types of FVIII products have led to varying implications on inhibitor development, ranging from definitive risk to no evidence of any correlation. 16 Most of the available data on incidence, prevalence and predisposing factors for inhibitor development are from developed countries with adequate access to factor concentrate replacement with the majority of patients being of Caucasian descent.
There is a paucity of data regarding the prevalence of inhibitors in severe haemophilia A from low and middle income countries (LMIC) and from different races and ethnicities. A previous study that published data in this regard from India showed an overall prevalence of 6.07% with a varying distribution of 4.17%, 4.89%, 5.45%
and 13.04% of inhibitors from Western, Eastern, Northern and Southern regions. 17 Several of these studies were not comprehensively designed and have a tertiary centre referral bias. In this study, we undertook a comprehensive community-based evaluation of severe haemophilia A patients to study the prevalence of inhibitors and its predisposing factors.
| MATERIAL S AND ME THODS

| Patient recruitment and sample collection
Patients were recruited from haemophilia treatment centres by physicians involved in haemophilia care through haemophilia chapters and from the haemophilia clinic of Department of Haematology, Christian
Medical College, Vellore, India ( Figure S1 ; Table S1 ). family history and particulars which were considered to be potential determinants of inhibitor formation were collected through the comprehensive questionnaire (Table S2 ). All the data in this study were collected from these questionnaires administered by trained staff supplemented where possible by chart reviews.
| Sample collection and DNA extraction
Plasma was separated from peripheral blood samples collected in citrated tubes (BD Biosciences, Franklin Lakes, NJ, USA) and transferred in dry ice to the laboratory at the Christian Medical College, Vellore. DNA was extracted from the K 3 EDTA tubes (Greiner BioOne, Kremsmünster, Austria), through standard phenol-chloroform method. Samples were collected in heparin tubes (Greiner Bio-One)
for flow cytometric analysis. Peripheral blood was collected from healthy volunteers and genomic DNA was used as controls for determining the allelic frequency.
| Coagulation factor and inhibitor assays
Prothrombin time (PT) and activated partial thromboplastin time Bethesda Units (BU) per mL was considered as positive for inhibitor status.
| Polymorphisms in immunoregulatory genes and HLA class typing
A subset of 60 inhibitor-positive patients was studied for polymorphisms. The polymorphisms were studied in the ratio of 1:2 of in- 
| Assessment of T-cell subsets
The An appropriate isotypic control was used to define positivity.
| FVIII gene mutations-intron 22 and intron 1 inversions
Intron 22 and intron 1 inversions were screened in a set of 60 inhibitor-positive patients. Intron 22 inversion was screened by long PCR/ inverse PCR as per published protocols. 18, 19 Samples negative for intron 22 inversion was analysed for intron 1 inversion as per previous published modified protocol from our lab.
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| Haplotype assessment
The haplotypes reported previously in exon 10 (G1679A), exon 14 (A2554G and C3951G) and exon 25 (A6940G) 20 were identified by sequencing. DNA sequencing was performed in the exons harbouring the variants. DNA sequencing was performed with fluorescently labelled di-deoxy nucleotide triphosphates using Big Dye Terminator cycle sequencing kit ver1.1 (Applied Biosystems). The PCR products were cleaned post wash using a magnetic bead-based method. High
Prep™ DTR (Magbio Genomics, Gaithersburg, MD, USA), a paramagnetic bead system was used to remove the unincorporated dye terminators after the sequencing PCR. The sequencing was performed in an automated sequencer; ABI-Hitachi 3130 Genetic Analyser (Applied Biosystems).
| Statistical analysis
Comparisons between inhibitor-positive and inhibitor-negative patients were performed using Mann-Whitney U test/chi-square test F I G U R E 1 Patient recruitment profile in the study. Patients were recruited by conducting medical camps with the help of local haemophilia chapters. Out of the 580 patients recruited, 133 patients were excluded from the study as detailed in the figure. We could identify 447 patients of which 87 (19.5%) was positive for inhibitors. When the inclusion criteria for the study (FVIII: C < 1% and ≥5 exposures of FVIII replacement products) were applied, 395 patients were identified to be eligible for further analysis. There were 83 (21%) patients who were inhibitor positive and 312 (78.9%) patients who were inhibitor negative in this subgroup as applicable. Relative risks were calculated together with their 95%
confidence intervals. For all tests, a 2-sided P value of 0.05 or less was considered statistically significant. SPSS 24.0 software (IBM Corp, Armonk, NY, USA) was used to perform statistical analysis.
| RE SULTS
| Patient characteristics
Among 580 patients that were screened for this study, 447 were enrolled ( Figure 1 ). 
| Clinical and environmental factors in inhibitor development
The familial history including parental consanguinity was collected. (Table S3) .
Bleeding events in the first year of life and for lifetime in inhibitor-positive and inhibitor-negative patients were analysed and is detailed in Table S3 . Besides a significant difference of history of intracranial bleeds observed between inhibitor-positive and inhibitor-negative patients (P = 0.008), there was no significant difference in the history of bleeding at any other anatomical site (Table S3 ). There was a significant increased risk of inhibitor formation among cases that were HLA DRB1*13 positive (RR = 2.04; 95% CI 1.06-3.911; P = 0.033) and this significance was retained in the hightitre subset. There was also a trend to decreased risk of inhibitor formation among those that were HLA-DRB1*07 positive and this TA B L E 2 Polymorphisms of immuneregulatory genes analysed in the study and inhibitor-negative (n = 10) patients confirmed all the patients were of H1 haplotype.
| T-cell subsets and genetic markers in inhibitor development
Total
TA B L E 1 Demographic characteristics of the patients involved in the study
| D ISCUSS I ON
The study identifies the prevalence of inhibitors in Indian population. 21 Considering the fact that the factor consumption is much less compared to the developed countries, we hypothesized that the prevalence of inhibitors in our population was likely to be significantly lower as was also suggested by some of the published data from other LMIC's. Additionally, we made an effort to comprehensively evaluate for known genetic and environmental factors that could potentially be predisposing our patients to develop inhibitors.
This study involved evaluation of 395 severe haemophilia A patients for factors that could predispose them to develop inhibitors.
The median age of patients recruited into the study was 18 years and the median age of diagnosis was around 1.5 years of age. The late age of diagnosis in our study group can be attributed to difference in the medical infrastructure as well as the general lack of information and awareness regarding bleeding disorders in the general public. 22 The number of patients whose parents were consanguineous was 91 (23%)
in the study cohort. The percentage of high familial haemophilia can be due to the fact that consanguineous marriages are common (20%-40%) in the south of India from where most of our patients were recruited. 23 There is a paucity of data in the literature regarding the incidence and prevalence of inhibitors in developing countries and a perception that the incidence and prevalence may be lower than estimated in the developed world. 24 The overall prevalence of inhibitors in our study population was 19.5% (87/447), which is consistent with figures reported in many developed countries. 16 It may be noted that nearly two thirds of the inhibitor patients had low-titre inhibitors (64.4% low titre; 35.6% high titre), it is possible that some of these could be transient in nature. Furthermore, our study included patients from a population where no one underwent immune tolerance induction. The recent SIPPET study has reported a cumulative incidence of 35.4% of inhibitors in both plasma-derived FVIII and recombinant factor VIII treatment arms. 25 India has the largest number of identified patients with haemophilia accounting for about 7% global number of patients with haemophilia. 21 The high rate of prevalence in India is especially significant in the context of the fact that the factor consumption in India is significantly lower than in the developed countries. 26 A study in the patients with Hispanic origin had reported a high prevalence (24.5%) of high-titre inhibitors when controlled for possible confounders such as age and use of prophylaxis. 27 Studies have also reported that the prevalence of inhibitors in black patients was twice than that in the white patients in the United States of America 8, 28 suggesting the possible influence of race on the risk of development of inhibitors. Association of age and first exposure has been identified in several studies as a risk factor for inhibitor development. Lorenzo et al 29 have identified that age of start of therapy can be a predictor of inhibitor risk although contradictory results have also been reported. 30 We have identified that even though the exposure was negligible in the first year of life in our country the prevalence of the inhibitor was high and there was no evidence of an association with exposures to factor concentrates in the first year of life and inhibitor formation. We observed a significant difference in the number of intracranial bleeds between inhibitor-positive and inhibitor-negative patients (P = 0.008). As the study was retrospective in nature, we could not asses the direct link between this particular event and inhibitor formation.
In our study, we surveyed the consumption of FFP/cryoprecipitate, plasma-derived or recombinant FVIII, and CFC's. The study was limited by its retrospective natures and absence of well-maintained records and reliance on memory in some cases. We could not find a correlation with either the type of factor concentrate replacement that was used or the quantity used and inhibitor formation in contrast to previously reported studies. 16, [31] [32] [33] We have analysed fourteen polymorphisms associated with autoimmune conditions. To the best of our knowledge, this is the largest class II molecules. 37 Previous studies on IL-4 -590C/T in autoimmune thyroid diseases, hypothyroidism (AIH) and Graves' disease (GD) have
shown the variant has a protective effect against the autoimmune disease especially GD, 38 though there was no reported association with inhibitor formation in haemophilia in prior studies. 14, 39 A previously reported study from India in severe haemophilia A (n = 119) did not find any association with any of the HLA alleles and risk of inhibitor formation. 40 In contrast, our data suggest and increased risk of inhibitor formation with HLA DRB1*13 and this significance was retained in the high-titre subset. There was also a trend to decreased risk of inhibitor formation among those that were HLA-DRB1*07 positive. It is recognized that there is significant heterogeneity in allele distribution of DRB1*07 and DRB1-13 in the Indian population. 
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A previous study from India has shown a higher incidence of H1 in the population. 43 When we sequenced randomly inhibitor-positive
(n = 10) and inhibitor-negative (n = 10) patients, all the patients were of H1 haplotype and hence we feel that the haplotype may not be a deciding factor in the Indian population in concurrence with the previous published that the haplotype mismatch of the FVIII sequence between the product and the patient may not be a contributing factor for inhibitor formation. 44, 45 In conclusion, we have identified that the overall prevalence of inhibitors in severe haemophilia is similar to that reported in the developed countries. The involvement of transient inhibitors would have also played a role, the analysis being cross-sectional in nature; an additional limitation of this study was that it relied predominantly on patient and family recall, especially when the data were collected from peripheral camps with limited record keeping facilities. From our data, it appears that genetic factors predominate in the development of inhibitors with less, if any, impact of environmental factors. Additional and detailed genetic studies are required to dissect out the possible mechanism of inhibitor formation in some patients.
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